Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis announces ‘work performance improvements’ for Ambien

Sanofi-Aventis announces ‘work performance improvements’ for Ambien

24th October 2007

Sanofi-Aventis has announced new data showing that patients with chronic insomnia experience significant improvements in work performance following treatment with 12.5mg Ambien tablets.

Following a new study, patients displayed improvements in output and time management over a 12 -week period compared with patients taking a placebo.

Milton Erman, chief medical officer of Avastra USA, stressed that the results added to the growing body of evidence which showed the treatment of chronic insomnia can improve next -day functioning.

“This study demonstrates that Ambien is not only an effective treatment option to help patients with chronic insomnia fall and stay asleep, but is also associated with significant improvements in work performance.”

Those who suffer from chronic insomnia have been shown to have a higher frequency of work-related problems including absenteeism, low job satisfaction and greater difficulty performing duties.

The results follow a Phase IIIB study which saw 728 patients with chronic primary insomnia treated with either Ambien or a placebo.

This week, Sanofi-Aventis also announced that Taxotere (doxetaxel) received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency as a treatment for locally advanced squamous cell carcinoma of the head and neck in conjunction with cisplatin and 5-flouracil.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.